Search - tctmd.com

Displaying 1 - 20 of 144

Sort: Relevancy | Date

Presentation AHA 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presenter: Steven E. Nissen

November 15, 2016

Presentation TCT 2016

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Presenter: Bernard J. Gersh, Felix Mahfoud, Ori Ben-Yehuda

November 01, 2016

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Aspirin and ADP Antagonists Pre- and Post-coronary Stent Implantation

Presenter: Duane S. Pinto, Dmitriy N. Feldman

October 30, 2016

Presentation TCT 2016

Personalized Medicine Where Are We in 2016?

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Anti-inflammatory Therapies for Atherosclerosis

Presenter: Robert A. Harrington, A. Michael Lincoff, Jean-Claude Tardif

October 30, 2016

Presentation TCT 2016

Heart Failure Advances (Ivabradine, ARNI, and More)

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Presenter: Robert A. Harrington, A. Michael Lincoff, Norman E. Lepor

October 30, 2016

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presenter: David J. Moliterno

October 30, 2016

Presentation TCT 2016

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

Presenter: Paul A. Gurbel, Harvey D. White

October 30, 2016

Presentation TCT 2016

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Sunil V. Rao

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Pharmacotherapy for Hybrid PCI/CABG Cases

Presenter: Sorin J. Brener, Franz-Josef Neumann, Laura Mauri

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Usman Baber

October 30, 2016

Presentation TCT 2016

ACS Case Presentation: Where Pharmacotherapy Failed

Presenter: C. Michael Gibson, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy Clinical Trial Design

Presenter: C. Michael Gibson, Daniel I. Simon, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With STEMI

Presenter: C. Michael Gibson, Daniel I. Simon, Sunil V. Rao

October 30, 2016

Advertisement

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Aspirin and ADP Antagonists Pre- and Post-coronary Stent Implantation

Personalized Medicine Where Are We in 2016?

Anti-inflammatory Therapies for Atherosclerosis

Heart Failure Advances (Ivabradine, ARNI, and More)

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Pharmacotherapy for Hybrid PCI/CABG Cases

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

ACS Case Presentation: Where Pharmacotherapy Failed

Limitations of Pharmacotherapy Clinical Trial Design

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content